PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.

In prostate cancer, prostate brachytherapy boost improves biochemical failure at 10 years but does not prolong long-term OS compared to EBRT boost.

Researchers and clinicians from six leading medical centers and academic institutions—including the University of California San Diego—have collaborated to develop a new artificial intelligence model ...

A recent integrative analysis of single-cell sequencing and single-cell spatial mapping of lymph node metastasis in breast ...

An Abergavenny man has slammed a Welsh car dealer after the car he purchased from them broke down three times after driving away from the forecourt.